Alzex Neuropharma Inc. (TRRI)
- Previous Close
0.0000 - Open
0.0610 - Bid 0.0610 x --
- Ask 0.2000 x --
- Day's Range
0.0610 - 0.0610 - 52 Week Range
0.0012 - 0.3030 - Volume
33 - Avg. Volume
490 - Market Cap (intraday)
106,874 - Beta (5Y Monthly) -49.02
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Alzex Neuropharma Inc., a development stage biopharmaceutical company, engages in developing therapeutics for the treatment of Alzheimer's Disease and other neurological diseases. The company was formerly known as Trinity Resources Inc. and changed its name to Alzex Neuropharma Inc. in December 2022. The company was incorporated in 1971 and is headquartered in Las Vegas, Nevada.
www.trinresinc.comRecent News: TRRI
View MorePerformance Overview: TRRI
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRRI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRRI
View MoreValuation Measures
Market Cap
106.87k
Enterprise Value
106.87k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.68%
Return on Assets (ttm)
-1.64%
Return on Equity (ttm)
2.85%
Revenue (ttm)
4.73M
Net Income Avi to Common (ttm)
32.05k
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
63.5k
Total Debt/Equity (mrq)
76.40%
Levered Free Cash Flow (ttm)
198.14k